Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 First vaccines targeting 'cruise ship virus' sail into clinical trials.

Literature DB >> 24013733

First vaccines targeting 'cruise ship virus' sail into clinical trials.

Cassandra Willyard.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2013 PMID： 24013733 DOI： 10.1038/nm0913-1076

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

× No keyword cloud information.

9 in total

1. The potential economic value of a human norovirus vaccine for the United States.

Authors: Sarah M Bartsch; Benjamin A Lopman; Aron J Hall; Umesh D Parashar; Bruce Y Lee
Journal: Vaccine Date: 2012-09-28 Impact factor: 3.641

2. Norovirus vaccine against experimental human Norwalk Virus illness.

Authors: Robert L Atmar; David I Bernstein; Clayton D Harro; Mohamed S Al-Ibrahim; Wilbur H Chen; Jennifer Ferreira; Mary K Estes; David Y Graham; Antone R Opekun; Charles Richardson; Paul M Mendelman
Journal: N Engl J Med Date: 2011-12-08 Impact factor: 91.245

3. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007.

Authors: Aron J Hall; Aaron T Curns; L Clifford McDonald; Umesh D Parashar; Ben A Lopman
Journal: Clin Infect Dis Date: 2012-04-04 Impact factor: 9.079

4. Norovirus and medically attended gastroenteritis in U.S. children.

Authors: Daniel C Payne; Jan Vinjé; Peter G Szilagyi; Kathryn M Edwards; Mary Allen Staat; Geoffrey A Weinberg; Caroline B Hall; James Chappell; David I Bernstein; Aaron T Curns; Mary Wikswo; S Hannah Shirley; Aron J Hall; Benjamin Lopman; Umesh D Parashar
Journal: N Engl J Med Date: 2013-03-21 Impact factor: 91.245

5. Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis.

Authors: Zhaochun Chen; Stanislav V Sosnovtsev; Karin Bok; Gabriel I Parra; Michelle Makiya; Liane Agulto; Kim Y Green; Robert H Purcell
Journal: J Virol Date: 2013-06-19 Impact factor: 5.103

2 in total

Review 1. Vaccine against norovirus.

Authors: Ming Tan; Xi Jiang
Journal: Hum Vaccin Immunother Date: 2014-05-05 Impact factor: 3.452

2. Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population.

Authors: Sudeep Karve; Girishanthy Krishnarajah; Jennifer S Korsnes; Adrian Cassidy; Sean D Candrilli
Journal: Hum Vaccin Immunother Date: 2014-04-14 Impact factor: 3.452

2 in total

First vaccines targeting 'cruise ship virus' sail into clinical trials.

1. The potential economic value of a human norovirus vaccine for the United States.

2. Norovirus vaccine against experimental human Norwalk Virus illness.

3. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007.

4. Norovirus and medically attended gastroenteritis in U.S. children.

5. Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis.

6. Norovirus P particle efficiently elicits innate, humoral and cellular immunity.

7. Duration of immunity to norovirus gastroenteritis.

8. Norovirus disease in the United States.

9. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice.

Review 1. Vaccine against norovirus.

2. Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population.